Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Taiko Pharmaceutical Co., Ltd. specializes in the development and manufacturing of specialty pharmaceuticals, particularly in the oncology and autoimmune disease sectors. Its competitive position is bolstered by a robust pipeline of innovative therapies and a strong presence in the Japanese market, with strategic partnerships enhancing its global reach.
Taiko generates revenue primarily through the sale of proprietary oncology and autoimmune disease therapies, leveraging its R&D capabilities to maintain pricing power. Its competitive advantages include a diversified product portfolio, strong regulatory compliance, and established relationships with healthcare providers.
Regulatory approvals for new oncology treatments
Partnership announcements for drug development
Changes in reimbursement policies affecting drug pricing
Market expansion into Southeast Asia
Regulatory changes impacting drug approval processes
Technological advancements leading to new treatment modalities
Increased competition from generic drug manufacturers
Emergence of biosimilars in the oncology space
Low liquidity risk due to a current ratio of 4.14
Potential risks associated with R&D investments not yielding expected results
moderate - demand for pharmaceuticals tends to be stable, but economic downturns can affect healthcare spending.
Low - the company has minimal debt, so rising interest rates have little impact on financing costs, but they could affect consumer spending on healthcare.
minimal - the company operates with a low debt/equity ratio of 0.06, indicating strong financial health.
growth - investors are likely attracted to the potential for significant revenue growth from new drug launches.
moderate - the stock has shown some volatility, with a 1-year return of 4.1%.
